keyword
https://read.qxmd.com/read/38432129/sense-and-anti-sense-role-of-fam83a-and-fam83a-as1-in-wnt-egfr-pi3k-emt-pathways-and-tumor-progression
#21
REVIEW
Chenshu Zhao, Xiaowen Li, Rui Zhang, Hao Lyu, Shuai Xiao, Dong Guo, Declan William Ali, Marek Michalak, Xing-Zhen Chen, Cefan Zhou, Jingfeng Tang
An increasing number of studies have shown that FAM83A, a member of the family with sequence similarity 83 (FAM83), which consists of eight members, is a key tumor therapeutic target involved in multiple signaling pathways. It has been reported that FAM83A plays essential roles in the regulation of Wnt/β-catenin, EGFR, MAPK, EMT, and other signaling pathways and physiological processes in models of pancreatic cancer, lung cancer, breast cancer, and other malignant tumors. Moreover, the expression of FAM83A could be significantly affected by multiple noncoding RNAs that are dysregulated in malignant tumors, the dysregulation of which is essential for the malignant process...
March 2, 2024: Biomedicine & Pharmacotherapy
https://read.qxmd.com/read/38416679/nova1-acts-as-an-oncogenic-rna-binding-protein-to-regulate-cholesterol-homeostasis-in-human-glioblastoma-cells
#22
JOURNAL ARTICLE
Yuhki Saito, Yanhong Yang, Misa Saito, Christopher Y Park, Kosuke Funato, Viviane Tabar, Robert B Darnell
NOVA1 is a neuronal RNA-binding protein identified as the target antigen of a rare autoimmune disorder associated with cancer and neurological symptoms, termed paraneoplastic opsoclonus-myoclonus ataxia. Despite the strong association between NOVA1 and cancer, it has been unclear how NOVA1 function might contribute to cancer biology. In this study, we find that NOVA1 acts as an oncogenic factor in a GBM (glioblastoma multiforme) cell line established from a patient. Interestingly, NOVA1 and Argonaute (AGO) CLIP identified common 3' untranslated region (UTR) targets, which were down-regulated in NOVA1 knockdown GBM cells, indicating a transcriptome-wide intersection of NOVA1 and AGO-microRNA (miRNA) targets regulation...
March 5, 2024: Proceedings of the National Academy of Sciences of the United States of America
https://read.qxmd.com/read/38412563/approaches-to-probe-and-perturb-long-noncoding-rna-functions-in-diseases
#23
REVIEW
Guiping Wang, Yannick Lee-Yow, Howard Y Chang
Long noncoding RNAs (lncRNAs) are a class of RNA molecules exceeding 200 nucleotides in length that lack long open-reading frames. Transcribed predominantly by RNA polymerase II (>500nt), lncRNAs can undergo splicing and are produced from various regions of the genome, including intergenic regions, introns, and in antisense orientation to protein-coding genes. Aberrations in lncRNA expression or function have been associated with a wide variety of diseases, including cancer, cardiovascular diseases, diabetes, and neurodegeneration...
February 26, 2024: Current Opinion in Genetics & Development
https://read.qxmd.com/read/38407689/lncrna-dguok-as1-promotes-cell-progression-in-lung-squamous-cell-carcinoma-by-regulation-of-mir-653-5p-slc6a15-axis
#24
JOURNAL ARTICLE
Yan Teng, Shixia Li, Lijuan Wei, Chi Zhang, Lijuan Li, Shuang Wang, Jing Zhang, Jinchao Huang, Huan Zhang, Nan Wu, Juntian Liu
Long noncoding RNA (lncRNA) plays a key role in regulating cancer development. LncRNA deoxyguanosine kinase antisense RNA 1 (DGUOK-AS1) has been reported as a promoter in tumor. The work was designed to further investigate the mechanism of action of DGUOK-AS1 in lung squamous cell carcinoma (LUSC). DGUOK-AS1 level in LUSC cells was measured using RT-qPCR. Counting Kit-8 assays and colony forming assays were performed to evaluate LUSC cell viability and proliferation. Transwell assays were performed to detect cell migration and invasion...
February 26, 2024: Molecular Biotechnology
https://read.qxmd.com/read/38398221/knockdown-of-antisense-noncoding-mitochondrial-rna-reduces-tumorigenicity-of-patient-derived-clear-cell-renal-carcinoma-cells-in-an-orthotopic-xenograft-mouse-model
#25
JOURNAL ARTICLE
Mariela Araya, Francisca Sepúlveda, Jaime Villegas, Luis Alarcón, Luis O Burzio, Verónica A Burzio, Vincenzo Borgna
Clear cell renal cell carcinoma (ccRCC) is the most prevalent form of renal cancer and its treatment is hindered by a resistance to targeted therapies, immunotherapies and combinations of both. We have reported that the knockdown of the antisense noncoding mitochondrial RNAs (ASncmtRNAs) with chemically modified antisense oligonucleotides induces proliferative arrest and apoptotic death in tumor cells from many human and mouse cancer types. These studies have been mostly performed in vitro and in vivo on commercially available cancer cell lines and have shown that in mouse models tumor growth is stunted by the treatment...
February 19, 2024: Cancers
https://read.qxmd.com/read/38391508/general-and-specific-cytotoxicity-of-chimeric-antisense-oligonucleotides-in-bacterial-cells-and-human-cell-lines
#26
JOURNAL ARTICLE
Katya B Popova, Robert Penchovsky
In the last two decades, antisense oligonucleotide technology has emerged as a promising approach to tackling various healthcare issues and diseases, such as antimicrobial resistance, cancer, and neurodegenerative diseases. Despite the numerous improvements in the structure and modifications of the antisense oligonucleotides (ASOs), there are still specific problems with their clinical efficacy and preclinical cytotoxicity results. To better understand the effects of the ASOs in this paper, we conducted many MTT assays to assess the general and specific cytotoxicity of four new chimeric ASOs in bacterial cells and human cell lines...
January 26, 2024: Antibiotics
https://read.qxmd.com/read/38383439/the-therapeutically-actionable-long-non-coding-rna-t-recs-is-essential-to-cancer-cells-survival-in-nras-mapk-driven-melanoma
#27
JOURNAL ARTICLE
Valentin Feichtenschlager, Linan Chen, Yixuan James Zheng, Wilson Ho, Martina Sanlorenzo, Igor Vujic, Eleanor Fewings, Albert Lee, Christopher Chen, Ciara Callanan, Kevin Lin, Tiange Qu, Dasha Hohlova, Marin Vujic, Yeonjoo Hwang, Kevin Lai, Stephanie Chen, Thuan Nguyen, Denise P Muñoz, Yoshinori Kohwi, Christian Posch, Adil Daud, Klemens Rappersberger, Terumi Kohwi-Shigematsu, Jean-Philippe Coppé, Susana Ortiz-Urda
Finding effective therapeutic targets to treat NRAS-mutated melanoma remains a challenge. Long non-coding RNAs (lncRNAs) recently emerged as essential regulators of tumorigenesis. Using a discovery approach combining experimental models and unbiased computational analysis complemented by validation in patient biospecimens, we identified a nuclear-enriched lncRNA (AC004540.4) that is upregulated in NRAS/MAPK-dependent melanoma, and that we named T-RECS. Considering potential innovative treatment strategies, we designed antisense oligonucleotides (ASOs) to target T-RECS...
February 22, 2024: Molecular Cancer
https://read.qxmd.com/read/38383342/long-noncoding-rna-tmpo-as1-accelerates-glycolysis-by-regulating-the-mir-1270-pkm2-axis-in-colorectal-cancer
#28
JOURNAL ARTICLE
Yingmin Jin, Aimin Jiang, Liying Sun, Yue Lu
BACKGROUND: Long noncoding RNA thymopoietin-antisense RNA 1 (TMPO-AS1) is recognized as a participant in cancer progression. Nevertheless, its biological function in colorectal cancer remains obscure and needs further elucidation. METHODS AND RESULTS: First, we discovered enriched TMPO-AS1 in the tumor tissues that were related to poor prognosis. TMPO-AS1 knockdown enhanced SW480 cell apoptosis but inhibited invasion, proliferation, migration, and glucose metabolism...
February 21, 2024: BMC Cancer
https://read.qxmd.com/read/38366205/roles-of-hotair-long-non-coding-rna-in-gliomas-and-other-cns-disorders
#29
REVIEW
Faraz Ahmad, Ravi Sudesh, A Toufeeq Ahmed, Shafiul Haque
HOX transcript antisense intergenic RNA (HOTAIR) is a long non-coding RNA (lncRNA) which is increasingly being perceived as a tremendous molecular mediator of brain pathophysiology at multiple levels. Epigenetic regulation of target gene expression carried out by HOTAIR is thorough modulation of chromatin modifiers; histone methyltransferase polycomb repressive complex 2 (PRC2) and histone demethylase lysine-specific demethylase 1 (LSD1). Incidentally, HOTAIR was the first lncRNA shown to elicit sponging of specific microRNA (miRNA or miR) species in a trans-acting manner...
February 16, 2024: Cellular and Molecular Neurobiology
https://read.qxmd.com/read/38364571/long-noncoding-rna-abhd11-as1-interacts-with-sart3-and-regulates-cd44-rna-alternative-splicing-to-promote-lung-carcinogenesis
#30
JOURNAL ARTICLE
Po-Shun Wang, Zulong Liu, Osama Sweef, Jie Xie, Jing Chen, Haining Zhu, Patti C Zeidler-Erdely, Chengfeng Yang, Zhishan Wang
Hexavalent chromium [Cr(VI)] is a common environmental pollutant and chronic exposure to Cr(VI) causes lung cancer in humans, however, the mechanism of Cr(VI) carcinogenesis has not been well understood. Lung cancer is the leading cause of cancer-related death, although the mechanisms of how lung cancer develops and progresses have been poorly understood. While long non-coding RNAs (lncRNAs) are found abnormally expressed in cancer, how dysregulated lncRNAs contribute to carcinogenesis remains largely unknown...
February 10, 2024: Environment International
https://read.qxmd.com/read/38361755/role-of-oncogenic-long-noncoding-rna-kcnq1ot1-in-colon-cancer
#31
JOURNAL ARTICLE
Gang Liu, Lei Shi, Bin Wang, Zehui Wu, Haiyuan Zhao, Tianyu Zhao, Lianghui Shi
The role of lncRNA KCNQ1 opposite strand/antisense transcript 1 (KCNQ1OT1) in colon cancer involves various tumorigenic processes and has been studied widely. However, the mechanism by which it promotes colon cancer remains unclear. Retroviral vector pSEB61 was retrofitted in established HCT116-siKCN and SW480-siKCN cells to silence KCNQ1OT1. Cellular proliferation was measured using CCK8 assay, and flow cytometry (FCM) detected cell cycle changes. RNA sequencing (RNA-Seq) analysis showed differentially expressed genes (DEGs)...
2024: Oncology Research
https://read.qxmd.com/read/38360008/rna-therapeutics-history-and-future-perspectives
#32
JOURNAL ARTICLE
Hong-Quan Duong, Minh-Cong Hoang, Thi-Hue Nguyen, Van-Lang Ngo, Van-Thu Le
Ribonucleic acid (RNA) therapeutics have significantly used RNA-based drugs to the prevention and treatment of diseases as effective messenger RNA-based vaccines in response to the COVID-19 pandemic. The RNA therapeutics with five classes including antisense oligonucleotide, small interfering RNA, microRNA, APTAMER and messenger RNAs are being quickly developed to treat various human diseases as neurological disease, cardiovascular disease, genetic and rare disease, cancer disease, coronavirus disease… which cannot be treated by other conventional drugs as small molecule-based drugs and antibodies...
2024: Progress in Molecular Biology and Translational Science
https://read.qxmd.com/read/38360001/rna-therapeutics-for-disorders-of-excretory-system
#33
JOURNAL ARTICLE
Thuy-Duong Vu, Mai Anh Nguyen, Adam Jurgoński, Dinh-Toi Chu
The excretory system is responsible for removing wastes from the human body, which plays a crucial role in our lives. Current treatments for diseases related to this system have shown several limitations; therefore, there is a rising need for novel methods. In this circumstance, RNA-based therapeutics have rapidly emerged as new and promising candidates. In fact, to date, a handful of potential drugs have passed the development step and entered the clinical pipeline. Among them, one drug received FDA approval to enter the global market, which is Oxlumo (Lumasiran) for the treatment of primary hyperoxaluria type 1...
2024: Progress in Molecular Biology and Translational Science
https://read.qxmd.com/read/38359994/recent-applications-of-rna-therapeutic-in-clinics
#34
JOURNAL ARTICLE
Huyen Trang Ha Thi, Van Thai Than
Ribonucleic acid (RNA) therapy has been extensively researched for several decades and has garnered significant attention in recent years owing to its potential in treating a broad spectrum of diseases. It falls under the domain of gene therapy, leveraging RNA molecules as a therapeutic approach in medicine. RNA can be targeted using small-molecule drugs, or RNA molecules themselves can serve as drugs by interacting with proteins or other RNA molecules. While several RNA drugs have been granted clinical approval, numerous RNA-based therapeutics are presently undergoing clinical investigation or testing for various conditions, including genetic disorders, viral infections, and diverse forms of cancer...
2024: Progress in Molecular Biology and Translational Science
https://read.qxmd.com/read/38358853/engineering-logic-dna-nanoprobes-on-live-cell-membranes-for-simultaneously-monitoring-extracellular-ph-and-precise-drug-delivery
#35
JOURNAL ARTICLE
Wanzhen Chen, Jingjing Lai, Siqi Dong, Lanlan Chen, Huanghao Yang
It remains a challenge to use a single probe to simultaneously detect extracellular pH fluctuations and specifically recognize cancer cells for precise drug delivery. Here, we engineered a tetrahedral framework nucleic acid-based logic nanoprobe (isgc8-tFNA) on live cell membranes for simultaneously monitoring extracellular pH and targeted drug delivery. Isgc8-tFNA was anchored stably on the cell surface through three cholesterol molecules inserting into the bilayer of the cell membrane. Once responding to the acidic tumor microenvironment, isgc8-tFNA formed an i-motif structure, leading to turn-on FRET signals for monitoring changes of extracellular pH...
February 15, 2024: Analytical Chemistry
https://read.qxmd.com/read/38355725/innate-and-adaptive-immune-cell-interaction-drives-inflammasome-activation-and-hepatocyte-apoptosis-in-murine-liver-injury-from-immune-checkpoint-inhibitors
#36
JOURNAL ARTICLE
Layla Shojaie, Jacob M Bogdanov, Helia Alavifard, Mahmoud G Mohamed, Aria Baktash, Myra Ali, Simeon Mahov, Sue Murray, Gary C Kanel, Zhang-Xu Liu, Fumito Ito, Gino K In, Akil Merchant, William Stohl, Lily Dara
Immune checkpoints (CTLA4 & PD-1) are inhibitory pathways that block aberrant immune activity and maintain self-tolerance. Tumors co-opt these checkpoints to avoid immune destruction. Immune checkpoint inhibitors (ICIs) activate immune cells and restore their tumoricidal potential, making them highly efficacious cancer therapies. However, immunotolerant organs such as the liver depend on these tolerogenic mechanisms, and their disruption with ICI use can trigger the unintended side effect of hepatotoxicity termed immune-mediated liver injury from ICIs (ILICI)...
February 14, 2024: Cell Death & Disease
https://read.qxmd.com/read/38351187/biomarker-directed-targeted-therapy-plus-durvalumab-in-advanced-non-small-cell-lung-cancer-a-phase-2-umbrella-trial
#37
JOURNAL ARTICLE
Benjamin Besse, Elvire Pons-Tostivint, Keunchil Park, Sylvia Hartl, Patrick M Forde, Maximilian J Hochmair, Mark M Awad, Michael Thomas, Glenwood Goss, Paul Wheatley-Price, Frances A Shepherd, Marie Florescu, Parneet Cheema, Quincy S C Chu, Sang-We Kim, Daniel Morgensztern, Melissa L Johnson, Sophie Cousin, Dong-Wan Kim, Mor T Moskovitz, David Vicente, Boaz Aronson, Rosalind Hobson, Helen J Ambrose, Sajan Khosla, Avinash Reddy, Deanna L Russell, Mohamed Reda Keddar, James P Conway, J Carl Barrett, Emma Dean, Rakesh Kumar, Marlene Dressman, Philip J Jewsbury, Sonia Iyer, Simon T Barry, Jan Cosaert, John V Heymach
For patients with non-small-cell lung cancer (NSCLC) tumors without currently targetable molecular alterations, standard-of-care treatment is immunotherapy with anti-PD-(L)1 checkpoint inhibitors, alone or with platinum-doublet therapy. However, not all patients derive durable benefit and resistance to immune checkpoint blockade is common. Understanding mechanisms of resistance-which can include defects in DNA damage response and repair pathways, alterations or functional mutations in STK11/LKB1, alterations in antigen-presentation pathways, and immunosuppressive cellular subsets within the tumor microenvironment-and developing effective therapies to overcome them, remains an unmet need...
February 13, 2024: Nature Medicine
https://read.qxmd.com/read/38347795/rna-based-therapeutics-past-present-and-future-prospects-challenges-in-cancer-treatment
#38
JOURNAL ARTICLE
Anjana Goel, Amisha Rastogi, Mansi Jain, Kinjal Niveriya
It is becoming more and harder in today's climate to disregard the impact of cancer on social health. Even though a significant amount of money is spent annually on cancer research, it still ranks as the second leading cause of death worldwide. Additionally, only about half of the patients suffering from complex forms of cancer survive a year after receiving traditional cancer therapies. A method for silencing genes is called RNA interference (RNAi). Such a method is very effective in focusing on genes linked to cancer...
February 12, 2024: Current Pharmaceutical Biotechnology
https://read.qxmd.com/read/38346399/an-endosomal-escape-trojan-horse-platform-to-improve-cytosolic-delivery-of-nucleic-acids
#39
JOURNAL ARTICLE
Steven Narum, Brendan Deal, Hiroaki Ogasawara, Joseph Nicholas Mancuso, Jiahui Zhang, Khalid Salaita
Endocytosis is a major bottleneck toward cytosolic delivery of nucleic acids, as the vast majority of nucleic acid drugs remain trapped within endosomes. Current trends to overcome endosomal entrapment and subsequent degradation provide varied success; however, active delivery agents such as cell-penetrating peptides have emerged as a prominent strategy to improve cytosolic delivery. Yet, these membrane-active agents have poor selectivity for endosomal membranes, leading to toxicity. A hallmark of endosomes is their acidic environment, which aids in degradation of foreign materials...
February 12, 2024: ACS Nano
https://read.qxmd.com/read/38342602/splicing-factor-pqbp1-curtails-bax-expression-to-promote-ovarian-cancer-progression
#40
JOURNAL ARTICLE
Xihan Liu, Jiaojiao Zhang, Zixiang Wang, Mingyao Yan, Meining Xu, Gaoyuan Li, Victoria Shender, Jian-Jun Wei, Jianqiao Li, Changshun Shao, Shiqian Zhang, Beihua Kong, Kun Song, Zhaojian Liu
Splicing factor polyglutamine binding protein-1 (PQBP1) is abundantly expressed in the central nervous system during development, and mutations in the gene cause intellectual disability. However, the roles of PQBP1 in cancer progression remain largely unknown. Here, it is shown that PQBP1 overexpression promotes tumor progression and indicates worse prognosis in ovarian cancer. Integrative analysis of spyCLIP-seq and RNA-seq data reveals that PQBP1 preferentially binds to exon regions and modulates exon skipping...
February 11, 2024: Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
keyword
keyword
54230
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.